Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02222285 · ClinicalTrials.gov registry record · NA

An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)

A NA study of Autistic Disorder, sponsored by Enzymotec.

Completed
Registry status
NA
Development phase
56
Enrollment target
2
Study locations

NCT02222285 is a NA study of Autistic Disorder that has completed, run by Enzymotec. The registered enrollment target is 56 participants, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02222285, a NA study of Autistic Disorder, has completed, sponsored by Enzymotec.

COMPLETED
Registry status
NA
Development phase
56 participants
Enrollment target
2
Study locations

Study Summary

The primary study objective is to evaluate the efficacy of Vayarin\_005 on ASD related symptoms in children.

Conditions Studied

Interventions

  • OTHER Placebo
  • OTHER Medical Food : Vayarin_005

Study Locations (2)

New Jersey

  • Institute of Neurology and Neurosurgery at St. Barnabas - Livingston

New York

  • Spectrum Neuroscience and Treatment Institute - New York

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2014-08
Est. Completion 2017-10
Phase NA

Sponsor

Enzymotec

3 total trials

What the Registry Record Tells You About NCT02222285

The ClinicalTrials.gov registry entry for NCT02222285 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 27 other Autistic Disorder trials with a reported enrollment target (50% lower). The listed sponsor is Enzymotec, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Autistic Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02222285 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT02222285 about?

NCT02222285 is a clinical study titled "An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)". The primary study objective is to evaluate the efficacy of Vayarin\_005 on ASD related symptoms in children.

What is the current status of trial NCT02222285?

This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2014-08. Estimated completion is 2017-10.

What conditions does trial NCT02222285 study?

This clinical trial studies the following conditions: Autistic Disorder.

What interventions are being tested in trial NCT02222285?

The interventions under investigation include: Placebo (OTHER), Medical Food : Vayarin_005 (OTHER).

Who is sponsoring clinical trial NCT02222285?

This trial is sponsored by Enzymotec, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02222285 being conducted?

This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autistic Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.